Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Aurora kinase inhibitors in preclinical and clinical testing

(2009) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer

(2008) Y. Nadler et al.   CLINICAL CANCER RESEARCH

415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations

(2008) Y. Lee et al.   EJC SUPPLEMENTS

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

(2008) J. Infante et al.   EJC SUPPLEMENTS

285 POSTER MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic-pharmacodynamic phase I study

(2008) J. Tabernero Caturla et al.   EJC SUPPLEMENTS